Predicine to Present Four Studies at 2023 ASCO Genitourinary (GU) Symposium Highlighting the Technical and Clinical Utility of Predicine’s Liquid Biopsy Based Assays   SILICON VALLEY, Calif., Feb. 16, 2023 — Predicine, a global molecular insights company, is committed to advancing genitourinary (GU) cancer detection and treatment decisions through its proprietary non-invasive next-generation sequencing (NGS)...